Brief: Cereno Scientific Obtains First Patent For Drug Candidate HDAC Inhibitor CS014
Jan 17 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* CERENO SCIENTIFIC OBTAINS FIRST PATENT FOR DRUG CANDIDATE HDAC INHIBITOR CS014 IN
DEVELOPMENT
FOR THROMBOSIS PREVENTION TREATMENT
* DRUG CANDIDATE CS014, A NOVEL HDAC INHIBITOR, HAS OBTAINED AN ISSUED PATENT IN UK.
Source text for Eikon: ID:nWkr7c777z
Further company coverage: CRNOSb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global